In recent years the use of MRI in patients with Crohn’s disease (CD) has increased. However, few data are available on how MRI parameters of active disease change during treatment with anti –TNF and whether these changes correspond to symptoms, serum biomarkers or endoscopic appearance [1, 2]. The aim of this study is to determine ifthe two currently used MRI scores, MaRIA (magnetic resonance index of activity) and the Clearmont score, can be employed to monitor treatment response to anti-TNF therapy in patients with CD,...

Patients population We performed a prospective single centre study of 36 patients with biopsy-proven diagnosis of active CD (22 males and 14 females; median age of 25,8 ys; age range, 18–47). All patients underwent ileo-colonoscopy, MRI at baseline and 26 weeks after anti - TNF therapy. Fecal calprotectin levels were collected before and after treatment. Inclusion criteria were as follows: age older than 18 years; moderately or severely active CD (as shown by a SES-CD score > 7 points); elevated fecal calprotectin level (>250 μg/g);...

A total of 180 segments were studies. Baseline characteristics of the patients are given in Table 4. Before the administration of the anti-TNF treatment, all patients had a faecal calprotectin level greater than 250 μg/g and a SES-CD > 3. For induction of remission, 26 patients (72%) were treated with IFX and 10 (28%) with ADA. At baseline, ADC values in active segments was significantly lower than in inactive segments (1.54 ± 0.45×10− 3 vs. 2.61 ± 0.33×10− 3 mm2 / s, respectively; p <...

DWI-MRI enterography is a reliable tool for evaluation of small intestine and colon inflammation avoiding administration of gadolinium-based contrast agent [9], moreover in association with dynamic contrast MRI provides quantitative measures of the phlogosis[10]. The DWI allows better sensitivity compared to DCE-MRI, while the combination of ADC and K (trans) parameters for the analysis can potentially improve specificity [11]. In conclusion, contrast enhanced MRI enterography provides an excellent assessment of the disease activity as well as the associated complications. MRI enterography in combination with DWI...

F. A. Carpagnano; Foggia/IT - nothing to disclose A. Lacanna; Foggia/IT - nothing to disclose M. R. Petrera; Foggia/IT - nothing to disclose A. N. Cintoli; Foggia/IT - nothing to disclose L. P. Stoppino; Foggia/IT - nothing to disclose R. Vinci; Foggia/IT - nothing to disclose L. Macarini; Foggia/IT - nothing to disclose

1.Ordas I, Rimola J, Rodriguez S et al. Accuracy of Magnetic Resonance Enterography in Assessing Response to Therapy and Mucosal Healing in Patients with Crohn’s Disease. Gastroenterology. 2014; 146: 374–382. 2.Van Assche G, Herrmann KA, Louis E, et al. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis 2013; 7:950–957. 3.Rimola J, Rodriguez S, Garcia-Bosch O, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut...